Apex Biotechnology Corp.

Taiwan Stock Exchange 1733.TW

Apex Biotechnology Corp. Price to Book Ratio (P/B) on January 14, 2025: 1.54

Apex Biotechnology Corp. Price to Book Ratio (P/B) is 1.54 on January 14, 2025, a -15.34% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Apex Biotechnology Corp. 52-week high Price to Book Ratio (P/B) is 1.99 on April 08, 2024, which is 28.83% above the current Price to Book Ratio (P/B).
Apex Biotechnology Corp. 52-week low Price to Book Ratio (P/B) is 1.44 on August 06, 2024, which is -6.46% below the current Price to Book Ratio (P/B).
Apex Biotechnology Corp. average Price to Book Ratio (P/B) for the last 52 weeks is 1.66.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Taiwan Stock Exchange: 1733.TW

Apex Biotechnology Corp.

CEO	Dr. Thomas Y. S. Shen Ph.D.
IPO Date	June 14, 2000
Location	Taiwan
Headquarters	No. 7, Li-Hsin 5th Road
Employees	641
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemoglobin screening systems. It also provides pesticide residues check systems; and care management and tele-health services. The company was founded in 1997 and is headquartered in Hsinchu City, Taiwan.

Key trends

Past 5 years